AKTIVAX, INC. — Department of Defense SBIR Phase II: AktiVax is developing ARAI, a versatile auto-injector platform that is robust, light-weigh

AKTIVAX, INC. — SBIR Phase II award from Department of Defense.

Amount
$552,400
Agency
Department of Defense · Office for Chemical and Biological Defense
Program / Phase
SBIR · Phase II
Solicitation
2013.1
NAICS
Place of performance
CO
Period
2014-06-30 → 2015-06-30

Description

AktiVax is developing ARAI, a versatile auto-injector platform that is robust, light-weight, intuitive and simple for self-administration of medical countermeasures. ARAI is designed with the Warfighter in mind for handling and operation single-handedly with compromised dexterity, while wearing protective gloves and gear . ARAI is a versatile platform that can be adapted to a range of payloads, in terms of product dose volume, number of product constituents that need to be safely stored and mixed just prior to injection, in a wet or dry format. In addition ARAI can accommodate a range of needle sizes and types.. In ARAI the beneficial injectable agent, or its constituents, are stored in a flexible package made from high barrier foil called ARCH Aseptic Reconstitution Cartridge Hybrid. ARCH features improved product stability profile as the beneficial agent comes in contact with a single, safe material, avoiding glass, silicone lubricants, metals, rubbers, and adhesive that are present in conventional syringes and can adversely affect product stability. The foil material provides an absolute barrier to moisture, oxygen, and UV and is inherently drop-proof.